Immunoassay News and Research RSS Feed - Immunoassay News and Research

Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Astute Medical previews upcoming AKI & CRRT 2015 conference to be held in San Diego

Astute Medical, Inc., developer of the NephroCheck® Test, today previewed the upcoming AKI & CRRT 2015 conference to be held in San Diego from February 17 to February 20. [More]
Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes. [More]
Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

bioMérieux, a world leader in the field of in vitro diagnostics, and Astute Medical, Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers, today announced that they have signed a global, semi-exclusive agreement regarding the development of a test for the early risk assessment of acute kidney injury (AKI). [More]
Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances. [More]
Proteomics market expected to experience continual growth

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013. [More]
Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie. [More]

Bio-Techne to acquire CyVek for $60M

Bio-Techne Corporation announced today that it has agreed to acquire CyVek, Inc. (CyVek) for $60 million in cash, plus a potential earn-out payment of up to $35 million based on CyVek revenue over the 30-month period following the closing and an additional potential earn-out payment based on CyVek revenue through 2020 in excess of $100 million. [More]
Canada funds 22 inventive ideas for improving health in low-resource countries

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries. [More]
SeraCare Life Sciences announces launch of new ACCURUN 501 C. difficile Control

SeraCare Life Sciences announces launch of new ACCURUN 501 C. difficile Control

SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of its new ACCURUN 501 C. difficile Control – the company's first molecular control product targeting hospital acquired infections. [More]
Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Techne Corporation, (d/b/a Bio-Techne) today reported its financial results for the fourth quarter and full year ended June 30, 2014. [More]
Alere announces financial results for quarter ended 2014

Alere announces financial results for quarter ended 2014

Alere Inc., a global leader in rapid diagnostics and health information solutions, today announced its financial results for the quarter ended June 30, 2014. [More]

Beckman ranks among industry's highest performing Service providers in clinical diagnostics

Committed to providing the solutions labs need to meet the challenges they face, Beckman Coulter Diagnostics has been ranked among the industry's highest performing Service providers in the clinical diagnostics industry in the 2014 IMV ServiceTrak Executive Summary Report. [More]
Addcare’s liquid handling systems, automated immunoassay workstations, customized systems

Addcare’s liquid handling systems, automated immunoassay workstations, customized systems

Addcare Bio-Tech Co., Ltd. provides advanced liquid handling systems, automated immunoassay workstations and customized systems. [More]
Chemclin's Anti-TB assay helps in qualitative determination of Anti-TB in human serum

Chemclin's Anti-TB assay helps in qualitative determination of Anti-TB in human serum

Chemclin's Anti-TB assay provides components for in-vitro qualitative determination of Antibody to Mycobacterium Tuberculosis (Anti-TB) in human serum or plasma by an indirect chemiluminescent assay method. [More]
Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance

Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance

In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories. [More]
Beckman announces national availability of Prostate Health Index

Beckman announces national availability of Prostate Health Index

Beckman Coulter Diagnostics, a global leader in prostate cancer diagnostics, announces national availability of the Prostate Health Index (phi)*, a simple, non‐invasive blood test that is three times more specific in detecting prostate cancer1 than PSA (prostate‐specific antigen). [More]
Novel device uses smartphone to measure cortisol concentration in saliva

Novel device uses smartphone to measure cortisol concentration in saliva

Researchers have developed a device that uses any smartphone to measure the cortisol concentration in saliva. The device was presented Tuesday, June 24, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. [More]
Ferring Pharmaceuticals, Roche partner to make personalised infertility treatment possible

Ferring Pharmaceuticals, Roche partner to make personalised infertility treatment possible

Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring's human cell line derived recombinant follicle-stimulating hormone (human rFSH), a gonadotrophin currently in phase III development. [More]
Newborn congenital adrenal hyperplasia screening justified

Newborn congenital adrenal hyperplasia screening justified

The Swedish neonatal screening programme successfully detected all cases of clinically classified salt-wasting congenital adrenal hyperplasia during a 26-year period, researchers report. [More]
Beckman Coulter to feature scientific data on the VERIS MDx System at ECCMID 2014

Beckman Coulter to feature scientific data on the VERIS MDx System at ECCMID 2014

As part Beckman Coulter’s commitment to advancing the field of molecular diagnostics the company will feature scientific data on the VERIS MDx System at the 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held on 10‐13 May in Barcelona, Spain. Researchers will present five studies on the VERIS system and the company will offer an educational symposium addressing issues in viral load monitoring. The VERIS MDx System and VERIS human Cytomegalovirus (CMV) Assay received CE Marks earlier this year. [More]